Clinical Trial Update: Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing doxorubicin and epirubicin in relation to cardiotoxicity in patients with diffuse large B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• Epirubicin (epirubicin)

Snippet

Sponsor: Fudan University | Conditions: Lymphoma | Phase 3 | Status: COMPLETED